Skip to content

CorMedix CRMD Accounts Receivable, after Allowance for Credit Loss

Accounts Receivable, after Allowance for Credit Loss at other companies

Baxter International logo
Baxter InternationalBAX

Other financials

Income statement

See full
Revenue$127.4M+226%
Gross profit$115.4M+207%
Operating income$63.7M+216%
Net income$38.6M+87.0%
EPS (diluted)$0.43+43.3%

Balance sheet

See full
Cash & equivalents$179.1M+170%
Total debt$4.3M+729%
Total equity$437.0M+280%
Total assets$815.6M+445%

Cash flow

See full
Operating cash flow$42.4M+115%
CapEx$729.0K+7,190%
Free cash flow$41.7M+111%

Valuation

See full
Market cap$605.65M-34.4%
P/E3.4×
P/S1.5×-9.6×

Profitability

See full
Gross margin91.9%-3.5pp
Operating margin48.4%
Net margin45.2%
FCF margin48.7%+38.8pp

Returns & leverage

See full
Return on equity65.6%
Debt / equity0.0×
Current ratio-1.2×

Where this comes from

Reported directly by CorMedix in its filing.

Tagged under the XBRL concept us-gaap:AccountsReceivableNet.

The official record: CorMedix’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about CorMedix's accounts receivable, after allowance for credit loss.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CorMedix's accounts receivable, after allowance for credit loss?
CorMedix (CRMD) reported accounts receivable, after allowance for credit loss of $600K in Q1 2026.
How has CorMedix's accounts receivable, after allowance for credit loss changed year-over-year?
CorMedix's accounts receivable, after allowance for credit loss decreased by 37.3% year-over-year, from $957.21K to $600K.
What is the long-term trend for CorMedix's accounts receivable, after allowance for credit loss?
Over 3 years (2020 to 2025), CorMedix's accounts receivable, after allowance for credit loss has grown at a 463.3% compound annual growth rate (CAGR), from $3.36K to $600K.